Earnings6 reported quarters · next on Jan 27, 2027
Earnings
Quarter
EPS
EPS expected
Revenue
Revenue expected
Result
Q3 FY2026reported Oct 26, 2026
$3.30
$2.93
$5.7B
$5.4B
EPS beatRevenue beat
Q2 FY2026reported Jul 27, 2026
$2.54
$2.29
$4.7B
$4.3B
EPS beatRevenue beat
Q1 FY2026reported Apr 27, 2026
$2.16
$2.08
$4.0B
$4.0B
EPS beatRevenue in line
Q4 FY2025reported Jan 28, 2026
$1.89
$1.74
$3.6B
$3.5B
EPS beatRevenue beat
Q3 FY2025reported Oct 27, 2025
$1.58
$1.47
$3.2B
$3.5B
EPS beatRevenue miss
Q2 FY2025reported Jul 28, 2025
$1.39
$1.24
$2.9B
$2.8B
EPS beatRevenue beat
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Written by GetSignal with AI from each earnings call; every brief quotes the executives' own words. Key facts are what the company said on the call, not our forecast. Not investment advice.
Each firm's latest price target on CLS, newest first
Firm
Rating
Target
Action
Date
Barclays
Overweight
$414
Raised from $406
Goldman Sachs
Conviction Buy
$435
Cut from $475
BMO Capital
Outperform
$400
Cut from $450
Bernstein
Outperform
$520
Initiated
FBN Securities
Outperform
$375
Initiated
UBS
Buy
$430
Target set
RBC Capital
Not stated
$450
Raised from $440
CIBC
Not stated
$500
Raised from $480
Wolfe Research
Outperform
$475
Target set
Stifel
Not stated
$500
Raised from $445
Rothschild & Co Redburn
Buy
$460
Initiated
Susquehanna
Positive
$510
Target set
TD Securities
Not stated
$350
Target set
Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.
4 other firms rated CLS in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 11, 2026.
13F filings13F positions as of Jun 30, 2026
Institutional holders
875 institutions reported Celestica shares in 13F filings for Jun 30, 2026.
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
5 of the 97 fund managers we track list CLS shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
STOCK Act5 disclosures of 5 on record · median 17d of the 45 allowed
Congress trades in CLS
Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
+2803.9%since the saleEstimated exit price $7.71, close on Wed Nov 6, 2019Current price $223.89, close on Tue Nov 10
Nov 6, 2019
Dec 11, 2019
35d
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
The largest estimated position is in the $15,001 - $50,000 band. Estimate, as of Nov 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.
A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.
What the filings on CLS show and how current they are.
Are insiders buying or selling CLS?
Across the 6 most recent open-market filings shown here, 0 were purchases and 6 were sales. 6 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded CLS?
Cleo Fields, Val T. Hoyle and Roger Marshall disclosed CLS transactions in the filings shown here.
Which members of Congress hold CLS?
2 members of Congress report a position in CLS in the estimate we hold as of Nov 10, 2026. The estimated positions belong to Cleo Fields and Lucy McBath. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are CLS trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 17 days, against the 45 the STOCK Act allows.